W. Leopold

发表

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1999, Journal of medicinal chemistry.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

N. Pryer, D. W. Fry, W. Elliott, 2004, Molecular cancer therapeutics.

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

A. Doherty, J. Warmus, A. Bridges, 2008, Bioorganic & medicinal chemistry letters.

Toxicity and anticancer activity of a new triazine antifolate (NSC 127755).

F. Schabel, B. J. Roberts, W. Leopold, 1982, Cancer research.

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

Alan R. Saltiel, A. Bridges, W. Leopold, 1999, Nature Medicine.

The influence of tumor size and environment on gene expression in commonly used human tumor lines

Michael Z. Man, Nicholas A. Gorski, W. Leopold, 2004, BMC Cancer.

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

A. Bridges, D. W. Fry, A. McMichael, 1994, Science.

Imaging the Laboratory Mouse in vivo

W. Leopold, P. McConville, D. Lister, 2012 .

Imaging Efficacy in Tumor Models

W. Leopold, P. McConville, V. Kaimal, 2011 .

2 Preclinical Models of Tumor Growth and Response

R. Lister, W. Elliott, W. Leopold, 2007 .

Cell Cycle and Biochemical Effects of PD 0183812

D. W. Fry, E. Dobrusin, W. Leopold, 2001, The Journal of Biological Chemistry.

Transplantable Syngeneic Rodent Tumors

Richard E. Moore, B. J. Roberts, W. Leopold, 2002 .

2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).

J. Warmus, A. Bridges, W. Leopold, 2008, Bioorganic & medicinal chemistry letters.

Cell Cycle and Biochemical Effects of PD 0183812 A POTENT INHIBITOR OF THE CYCLIN D-DEPENDENT KINASES CDK4 AND CDK6*

D. W. Fry, E. Dobrusin, W. Leopold, 2001 .

Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues.

B. J. Roberts, W. Leopold, J. Nelson, 1984, Cancer research.

The biochemical pharmacology of (2'-R)-chloropentostatin, a novel inhibitor of adenosine deaminase.

W. Leopold, R. Jackson, D. Ross, 1986, Advances in enzyme regulation.

Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice

M. Kunkel, W. Elliott, B. J. Roberts, 1995, Investigational New Drugs.

Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.

W. Leopold, J. Nelson, R. Jackson, 1985, Cancer research.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

W. Denny, A. Doherty, A. Bridges, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Amino‐terminal sequence determinants for substrate recognition by platelet‐derived growth factor receptor tyrosine kinase

W. Leopold, W. Miller, P. M. Chan, 1996, FEBS letters.

Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide).

D. W. Fry, W. Leopold, R. Jackson, 1985, Biochemical pharmacology.

Transplantable Syngeneic Rodent Tumors: Solid Tumors in Mice

Richard E. Moore, B. J. Roberts, W. Leopold, 2011 .

The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity.

D. W. Fry, B. J. Roberts, W. Leopold, 1985, Advances in Enzyme Regulation.

The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential

A. Bridges, W. Leopold, J. Sebolt-Leopold, 2004 .

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

D. Boschelli, D. W. Fry, S. Trumpp-Kallmeyer, 2000, Journal of medicinal chemistry.

Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.

H. D. Showalter, W. Leopold, R. Jackson, 1987, Journal of medicinal chemistry.

Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane.

J. Miller, W. Leopold, E. Miller, 1981, Cancer research.

Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles.

D. W. Fry, W. Leopold, J. Lown,, 1986, Anti-cancer drug design.

A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.

W. Leopold, J. Sebolt-Leopold, M. Suto, 1991, Journal of medicinal chemistry.

5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.

H. D. Showalter, W. Leopold, R. Jackson, 1984, Journal of medicinal chemistry.

Carcinogenicity of Antitumorcis-Platinum ( ll ) Coordination Complexes in the Mouse and Rat 1

W. Leopold, E. Miller, J. Miller, 2006 .

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.

W. Denny, H. D. Showalter, J. M. Hamby, 2000, Journal of medicinal chemistry.

Comparison of some carcinogenic, mutagenic, and biochemical properties of S-vinylhomocysteine and ethionine.

J. Miller, W. Leopold, E. Miller, 1982, Cancer research.

S--vinyl homocysteine, an analog of ethionine that is highly mutagenic for S. typhimurium TA100.

J. Miller, W. Leopold, E. Miller, 1979, Biochemical and biophysical research communications.

Dezaguanine mesylate: a new antipurine antimetabolite

D. W. Fry, W. Leopold, R. Jackson, 2004, Investigational New Drugs.

Biochemical pharmacology and antitumor properties of

D. W. Fry, W. Leopold, R. Jackson, 1989 .

Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

F. Schabel, B. J. Roberts, W. Leopold, 1984, Cancer research.

Biological effects of acetomycin. I. Activity against tumor cells in vitro and in vivo.

D. V. Von Hoff, W. Leopold, K. Hamelehle, 1987, The Journal of antibiotics.

Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibiotic.

D. W. Fry, W. Leopold, R. Jackson, 1987, Advances in enzyme regulation.

Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor.

J. Christensen, D. W. Fry, W. Elliott, 2005, Molecular cancer therapeutics.

Preclinical Models of Tumor Growth and Response

R. Lister, W. Elliott, W. Leopold, 2007 .

Carcinogenicity of antitumor cis-platinum(II) coordination complexes in the mouse and rat.

J. Miller, W. Leopold, E. Miller, 1979, Cancer research.

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Jun Yu Li, T. Lawrence, A. Kraker, 2001, Cancer research.

Preclinical antitumor activity of CI-994

P. LoRusso, W. Leopold, M. Bissery, 2004, Investigational New Drugs.

Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo

A. Chinnaiyan, T. Lawrence, W. Leopold, 2004, Clinical Cancer Research.

C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

A. Doherty, D. Mcnamara, E. Dobrusin, 1997, Journal of medicinal chemistry.

CHAPTER 3 – GROWTH FACTOR AND SIGNAL TRANSDUCTION TARGETS FOR CANCER THERAPY

A. Bridges, D. W. Fry, A. Kraker, 2002 .

Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents

J. M. Shaw, A. Wozniak, P. LoRusso, 1995 .

Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.

A. Wozniak, P. LoRusso, W. Leopold, 1990, Cancer research.

In vivo activity of the novel anticancer antibiotic pd 110,161. Abstr.

B. J. Roberts, W. Leopold, J. M. Nelson, 1983 .

Regulation of metastasis‐related gene expression by p53: A potential clinical implication

M. Wicha, W. Leopold, Yi Sun, 1999, Molecular carcinogenesis.

Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.

James T. Elder, E. Wagner, R. Derynck, 2001, Neoplasia.

Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.

D. W. Fry, H. D. Showalter, W. Elliott, 1994, Anti-cancer drug design.

Biochemical pharmacology of the lipophilic antifolate, trimetrexate.

D. W. Fry, W. Leopold, R. Jackson, 1984, Advances in enzyme regulation.

Activity of the pyrazoloacridines against multidrug-resistant tumor cells

W. Leopold, R. Jackson, K. Hamelehle, 2004, Cancer Chemotherapy and Pharmacology.

Biological and biochemical activities of the novel antitumor antibiotic PD 114,759 and related derivatives

D. W. Fry, W. Leopold, J. Shillis, 2004, Investigational New Drugs.

Dynamic imaging of emerging resistance during cancer therapy.

Bradford A Moffat, Timothy D Johnson, Alnawaz Rehemtulla, 2006, Cancer research.

The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent.

W. Leopold, R. Jackson, J. Shillis, 1990, Cancer investigation.

Preclinical studies with trimetrexate: a review of conclusions and unanswered questions.

D. W. Fry, W. Leopold, R. Jackson, 1988, Seminars in oncology.

Cell cycle effects of trimetrexate (CI-898)

B. J. Roberts, W. Leopold, J. Nelson, 2004, Cancer Chemotherapy and Pharmacology.

Antitumor Efficacy of PD 115934 ( NSC 366140 ) against Solid Tumors of Mice 1

A. Wozniak, P. LoRusso, W. Leopold, 2006 .

In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721)

B. J. Roberts, W. Leopold, K. Hamelehle, 2004, Cancer Chemotherapy and Pharmacology.

Magnetic Resonance Imaging Determination of Tumor Grade and Early Response to Temozolomide in a Genetically Engineered Mouse Model of Glioma

B. Ross, A. Rehemtulla, E. Holland, 2007, Clinical Cancer Research.

Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)] (2 methyl-1,4-butane-diamine-N,N′)platinum

W. Elliott, B. J. Roberts, A. Kraker, 1991, Investigational new drugs.

In vivo and in vitro evaluation of the alkylating agent carmethizole.

D. W. Fry, W. Elliott, W. Leopold, 1991, Cancer research.

Chemical Approaches to Improved Radiotherapy

W. Leopold, J. Sebolt-Leopold, 1992 .

Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.

K. Beningo, T. Heffner, W. Elliott, 1992, International journal of radiation oncology, biology, physics.

Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.

A. Wozniak, I. Massova, W. Leopold, 1993, Journal of medicinal chemistry.

5-((AMINOALKYL)AMINO)-SUBSTITUTED ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONES AS NOVEL ANTICANCER AGENTS. SYNTHESIS AND BIOLOGICAL EVALUATION

H. D. Showalter, W. Leopold, R. Jackson, 1984 .

Collagen-production inhibitors evaluated as antitumor agents.

M. Wicha, W. Leopold, J. Tunac, 1985, Journal of the National Cancer Institute.

Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine: a novel mechanism for antitumor activity.

D. W. Fry, W. Leopold, R. Jackson, 1993, Molecular pharmacology.

Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.

W. Elliott, W. Leopold, C. Howard, 1994, Cancer research.

Histidylbenzylglycinamides A novel class of farnesyl diphosphate-competitive peptidic farnesyltransferase inhibitors

W. Leopold, D. Leonard, J. Leopold, 2001 .

Pyrido[2,3-d]pyrimidin-7-one Inhi-bitors of Cyclin-Dependent Kinases.

D. Boschelli, S. Trumpp-Kallmeyer, D. Mcnamara, 2001 .

Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models

P. Vrignaud, W. Leopold, M. Chiron, 2007 .

Pyrazole derivatives. 5. Synthesis and antineoplastic activity of 3-(2-chloroethyl)-3,4-dihydro-4-oxopyrazolo[5,1-d]-1,2,3, 5-tetrazine-8-carboxamide and related compounds.

W. Leopold, E. Elslager, L. M. Werbel, 1986, Journal of Medicinal Chemistry.

Pyrazole Derivatives. Part 5. Synthesis and Antineoplastic Activity of 3-(2-Chloroethyl)-3,4-dihydro-4-oxopyrazolo(5,1-d)-1,2,3,5-tetrazine-8- carboxamide and Related Compounds.

W. Leopold, E. Elslager, L. M. Werbel, 1987 .

Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.

D. W. Fry, W. Elliott, P. Vincent, 1999, Anticancer research.

Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor

J. Christensen, D. W. Fry, W. Elliott, 2005, Molecular Cancer Therapeutics.